Form 4: Alnylam Director Amy Schulman Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Amy W. Schulman was granted 838 restricted stock units and 1,802 stock options as part of annual compensation.
Summary
- Director Amy W. Schulman acquired 838 restricted stock units (RSUs) on May 20, 2026.
- The director was also granted 1,802 stock options with an exercise price of $298.48.
- Both the RSUs and stock options vest on the earlier of the first anniversary of the grant date or the director's retirement/resignation (if within 90 days of the anniversary).
- Following these transactions, the director holds 24,049 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified; this is a standard compensatory equity grant for a board member.
Risks
- Market volatility affecting the value of equity-based compensation.
- Potential dilution of existing shareholders, though the scale is minimal.
Future Outlook
The equity grants are subject to standard vesting schedules tied to continued service or retirement, aligning the director's tenure with company performance.
Management Comments
- The grants were issued under the Second Amended and Restated 2018 Stock Incentive Plan.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure governance alignment and retain experienced leadership.
Comparison to Industry Standards
- The use of RSUs and stock options for board compensation is consistent with standard practices for mid-to-large cap pharmaceutical companies.
- Vesting periods of one year are typical for annual director equity refreshers in the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of RSUs and stock options to Director Amy W. Schulman. | 05/20/2026 | Standard alignment of director incentives. |
Stakeholder Impact
- Minimal impact on shareholders due to the small size of the grant relative to total outstanding shares.
Next Steps
- Vesting of equity grants on May 20, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/20/2026 | Transaction date for RSU and stock option grants. |
| 05/20/2027 | Vesting date for stock options and RSUs. |
| 05/20/2036 | Expiration date for stock options. |
Keywords
Alnylam Pharmaceuticals, ALNY, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.